Patent: 9,289,509
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,289,509
| Title: | Uses of immunoconjugates targeting CD138 |
| Abstract: | Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination. |
| Inventor(s): | Osterroth; Frank (Dietzenbach, DE), Uherek; Christoph (Seligenstadt, DE), Bruecher; Christoph (Eschborn, DE), Daelken; Benjamin (Frankfurt am Main, DE), Engling; Andre (Frankfurt, DE), Haeder; Thomas (Dreieichenhain, DE), Wartenberg-Demand; Andrea (Linden, DE), Niemann; Gabriele (Karlsruhe, DE), Zuber; Chantal (Frankfurt, DE), Czeloth; Niklas (Dreieich, DE), Aigner; Silke (Frankenthal, DE), Zeng; Steffen (Muenster, DE), Schulz; Gregor (Umkirch, DE) |
| Assignee: | Biotest AG (Dreieich, DE) Immunogen Inc. (Waltham, MA) |
| Application Number: | 12/774,705 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,289,509
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2029-05-06 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2029-05-06 |
| Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | See Plans and Pricing | 2029-05-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
